Toremifene for breast cancer: A review of 20 years of data

Clinical Breast Cancer

Volumn 14, Issue 1, 2014, Pages 1-9

  Vogel, Charles L ^a   Johnston, Mary Ann ^b   Capers, Christi ^b   Braccia, Deborah ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b GTx Inc   (United States)

^c Clinical Development   (United States)

Author keywords

Adjuvant therapy; Breast cancer hormonal therapy, CYP2D6, Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BONE DENSITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; HORMONAL THERAPY; HORMONE SENSITIVITY; HUMAN; LIPID BLOOD LEVEL; METABOLISM; ONCOLOGIST; POSTMENOPAUSE; REVIEW; THROMBOSIS;

ADJUVANT THERAPY; BREAST CANCER HORMONAL THERAPY, CYP2D6, SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TOREMIFENE;

EID: 84892696212     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.014     Document Type: Review

References (63)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. National Cancer Institute Trends Progress Report - 2011/2012 Update 2012 National Cancer Institute Bethesda, MD Available at http://progressreport. cancer.gov Accessed February 20, 2013
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer, V1.2013. Available at http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed February 20, 2013.
4. Personalized Medicine Coalition The case for personalized medicine 3rd ed 2011 Personalized Medicine Coalition New York, NY Available at www.personalizedmedicinecoalition.org/sites/default/files/files/ Case-for-PM-3rd-edition.pdf Accessed February 19, 2013
5. S. Paik, S. Shak, and G. Tang et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
6. A.M. Glas, A. Floore, and L.J. Delahaye et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 2006 278
7. G. Arpino, D. Generali, and A. Sapino et al. Gene expression profiling in breast cancer: a clinical perspective Breast 22 2013 109 120
8. R. Goncalves, and R. Bose Using multigene tests to select treatment for early-stage breast cancer J Natl Compr Canc Netw 11 2013 174 182 quiz 182
9. Y. Gokmen-Polar, and S. Badve Molecular profiling assays in breast cancer: are we ready for prime time? Oncology (Williston Park) 26 2012 350 357 361
10. ® as an additional treatment decision tool in early breast cancer Expert Rev Anticancer Ther 13 2013 179 194
11. American Medical Association. Personalized health care report 2008: warfarin and genetic testing. Available at: http://www.ama-assn.org/ama1/pub/ upload/mm/464/warfarin-brochure.pdf. Accessed: February 20, 2013.
12. ® [package insert] 2012 Prostrakan Inc Bridgewater NJ Available at: http://www.fareston.com/uploads/documents/fareston-pi.pdf Accessed: June 1, 2013
13. L. Kangas Review of the pharmacological properties of toremifene J Steroid Biochem 36 1990 191 195
14. L. Kangas, A.L. Nieminen, and K. Cantell Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cells in vitro Med Biol 63 1985 187 190
15. Y. Jin, Z. Desta, and V. Stearns et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 2005 30 39
16. M.P. Goetz, A. Kamal, and M.M. Ames Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response Clin Pharmacol Ther 83 2008 160 166
17. S. Borges, Z. Desta, and L. Li et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 2006 61 74
18. S. Borges, Z. Desta, and Y. Jin et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients J Clin Pharmacol 50 2010 450 458
19. V. Stearns, M.D. Johnson, and J.M. Rae et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 2003 1758 1764
20. J. Kim, C.C. Coss, and C.M. Barrett et al. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen Int J Cancer 132 2012 1475 1485
21. M.P. Goetz, S.K. Knox, and V.J. Suman et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 2007 113 121
22. E. Coezy, J.L. Borgna, and H. Rochefort Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res 42 1982 317 323
23. V.J. Wiebe, C.C. Benz, and I. Shemano et al. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer Cancer Chemother Pharmacol 25 1990 247 251
24. C.M. Kelly, and K.I. Pritchard CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned J Natl Cancer Inst 104 2012 427 428
25. J.M. Rae, S. Drury, and D.F. Hayes et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients J Natl Cancer Inst 104 2012 452 460
26. M.M. Regan, B. Leyland-Jones, and M. Bouzyk et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial J Natl Cancer Inst 104 2012 441 451
27. H. Brauch, W. Schroth, and M.P. Goetz et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters J Clin Oncol 31 2013 176 180
28. M.P. Goetz, V.J. Suman, and T.L. Hoskin et al. CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8 Clin Cancer Res 19 2013 500 507
29. K. Sideras, J.N. Ingle, and M.M. Ames et al. Coprescription of tamoxifen and medications that inhibit CYP2D6 J Clin Oncol 28 2010 2768 2776
30. D.L. Hertz, H.L. McLeod, and W.J. Irvin Jr. Tamoxifen and CYP2D6: a contradiction of data Oncologist 17 2012 620 630
31. M. Gershanovich, A. Garin, and D. Baltina et al. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group Breast Cancer Res Treat 45 1997 251 262
32. D.F. Hayes, J.A. Van Zyl, and A. Hacking et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer J Clin Oncol 13 1995 2556 2566
33. S. Pyrhonen, R. Valavaara, and H. Modig et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study Br J Cancer 76 1997 270 277
34. K. Holli, R. Valavaara, and G. Blanco et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group J Clin Oncol 18 2000 3487 3494
35. International Breast Cancer Study Group, O. Pagani, and S. Gelber et al. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93 Ann Oncol 15 2004 1749 1759
36. J.D. Lewis, A.B. Chagpar, and E.A. Shaughnessy et al. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer Cancer 116 2010 2307 2315
37. K. Holli, and Finnish Breast Cancer Group Tamoxifen versus toremifene in the adjuvant treatment of breast cancer Eur J Cancer 38 2002 S37 S38
38. W.B. Zhou, Q. Ding, and L. Chen et al. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials Breast Cancer Res Treat 128 2011 625 631
39. R. Zeynalov, I. Musaev, and S. Giyasbelli Comparative analysis of the efficacy of toremifene, tamoxifen and letrozole in treatment of patients with disseminated breast cancer Onkologiya 8 2006 131 134
40. P. Goss, I.N. Bondarenko, and G.N. Manikhas et al. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer J Clin Oncol 25 2007 4961 4966
41. A. Howell, J. Cuzick, and M. Baum et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
42. H. Iwase, Y. Yamamoto, and T. Ishikawa et al. Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer J Clin Oncol 30 2012 abstract 105
43. M. Sawaki, M. Wada, and Y. Sato et al. High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: a multicenter phase II study Oncol Lett 3 2012 61 65
44. Y. Yamamoto, N. Masuda, and T. Ohtake et al. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor Breast Cancer 17 2010 254 260
45. C.L. Vogel Phase II and III clinical trials of toremifene for metastatic breast cancer Oncology (Williston Park) 12 1998 9 13
46. C.L. Vogel, I. Shemano, and J. Schoenfelder et al. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer J Clin Oncol 11 1993 345 350
47. Gams RA, Vogel CL. Toremifene (TOR): an active agent in the management of postmenopausal women with advanced breast cancer refractory to tamoxifen (TAM). Paper presented at: American Society of Clinical Oncology; May 15-18, 1999; Atlanta, GA. Abstract 504.
48. K. Asaishi, T. Tominaga, and O. Abe et al. Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer [in Japanese] Gan To Kagaku Ryoho 20 1993 91 99
49. R.A. Gams, and A. Hajba High dose toremifene (TOR) in the management of advanced breast cancer refractory to tamoxifen (TAM and other therapies) Proc Natl Acad Sci USA 21 2002 abstract 215
50. S.H. Ahn, B.H. Son, and S.W. Kim et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea - a report from the Korean Breast Cancer Society J Clin Oncol 25 2007 2360 2368
51. R. Gu, W. Jia, and Y. Zeng et al. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study BMC Cancer 12 2012 161
52. S. Oksa, T. Luukkaala, and J. Maenpaa Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study BJOG 113 2006 713 718
53. R. Erkkola, L. Mattila, and T. Powles et al. Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women Breast Cancer Res Treat 93 2005 277 287
54. ® (Tamoxifen citrate) tablets [package insert] 2004 AstraZeneca Pharmaceuticals LP Wilmington, DE Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/17970s053lbl.pdf Accessed: February 20, 2013
55. M.R. Carnethon, M.S. Anthony, and W.E. Cascio et al. A prospective evaluation of the risk of QT prolongation with hormone replacement therapy: the atherosclerosis risk in communities study Ann Epidemiol 13 2003 530 536
56. L. Slovacek, V. Ansorgova, and Z. Macingova et al. Tamoxifen-induced QT interval prolongation J Clin Pharm Ther 33 2008 453 455
57. Science Foundation of Arizona. Available at: www.crediblemeds.org/ everyone/composite-listall-qtdrugs/?rf=US. Accessed: November 21, 2013.
58. B. Fisher, J.P. Costantino, and C.K. Redmond et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 1994 527 537
59. E. Pukkala, P. Kyyronen, and R. Sankila et al. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study Int J Cancer 100 2002 337 341
60. M. Kusama, K. Miyauchi, and H. Aoyama et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer Breast Cancer Res Treat 88 2002 1 8
61. M. Kusama, H. Kaise, and S. Nakayama et al. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations Breast Cancer Res Treat 88 2004 9 16
62. M.B. Marttunen, P. Hietanen, and A. Tiitinen et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients J Clin Endocrinol Metab 83 1998 1158 1162
63. K. Holli Adjuvant trials of toremifene vs tamoxifen: the European experience Oncology (Williston Park) 12 1998 23 27